Fulgent Genetics (FLGT) Projected to Post Earnings on Friday

Fulgent Genetics (NASDAQ:FLGT) will likely be posting its Q3 2025 results before the market opens on Friday, November 7th. Analysts expect Fulgent Genetics to post earnings of ($0.2242) per share and revenue of $81.43 million for the quarter. Individuals may visit the the company’s upcoming Q3 2025 earningresults page for the latest details on the call scheduled for Friday, November 7, 2025 at 8:30 AM ET.

Fulgent Genetics (NASDAQ:FLGT) last released its quarterly earnings data on Friday, August 1st. The company reported $0.07 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.30. The company had revenue of $81.80 million during the quarter, compared to analysts’ expectations of $76.21 million. Fulgent Genetics had a negative net margin of 16.83% and a negative return on equity of 2.26%. The firm’s quarterly revenue was up 15.2% on a year-over-year basis. During the same period in the previous year, the company earned $0.15 EPS. On average, analysts expect Fulgent Genetics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Fulgent Genetics Price Performance

Fulgent Genetics stock opened at $22.58 on Friday. The stock has a market cap of $691.17 million, a price-to-earnings ratio of -13.60 and a beta of 0.97. Fulgent Genetics has a 1 year low of $14.57 and a 1 year high of $24.64. The firm has a 50-day moving average of $22.50 and a two-hundred day moving average of $20.67.

Insider Buying and Selling

In related news, COO Jian Xie sold 1,199 shares of the stock in a transaction that occurred on Wednesday, August 27th. The shares were sold at an average price of $21.48, for a total transaction of $25,754.52. Following the completion of the sale, the chief operating officer owned 365,249 shares of the company’s stock, valued at $7,845,548.52. This represents a 0.33% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Insiders have sold a total of 5,577 shares of company stock worth $121,024 over the last three months. Corporate insiders own 31.76% of the company’s stock.

Institutional Investors Weigh In On Fulgent Genetics

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Goldman Sachs Group Inc. lifted its position in Fulgent Genetics by 28.7% during the first quarter. Goldman Sachs Group Inc. now owns 202,820 shares of the company’s stock valued at $3,428,000 after acquiring an additional 45,279 shares during the last quarter. BNP Paribas Financial Markets lifted its position in Fulgent Genetics by 2.5% during the second quarter. BNP Paribas Financial Markets now owns 87,318 shares of the company’s stock valued at $1,736,000 after acquiring an additional 2,128 shares during the last quarter. Canada Pension Plan Investment Board purchased a new stake in Fulgent Genetics during the second quarter valued at approximately $1,598,000. Russell Investments Group Ltd. increased its stake in Fulgent Genetics by 136.4% during the 2nd quarter. Russell Investments Group Ltd. now owns 68,324 shares of the company’s stock valued at $1,348,000 after purchasing an additional 39,418 shares in the last quarter. Finally, American Century Companies Inc. increased its stake in Fulgent Genetics by 8.0% during the 2nd quarter. American Century Companies Inc. now owns 52,168 shares of the company’s stock valued at $1,037,000 after purchasing an additional 3,860 shares in the last quarter. Hedge funds and other institutional investors own 48.06% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on FLGT. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Fulgent Genetics in a research report on Wednesday, October 8th. Piper Sandler set a $21.00 price target on shares of Fulgent Genetics and gave the stock a “neutral” rating in a research report on Monday, August 4th. Finally, UBS Group raised shares of Fulgent Genetics from a “neutral” rating to a “buy” rating and upped their price target for the stock from $20.00 to $30.00 in a research report on Tuesday, August 5th. Two research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Fulgent Genetics presently has an average rating of “Hold” and an average price target of $25.33.

About Fulgent Genetics

Fulgent Genetics, Inc, together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company’s clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.